Venetoclax (Venclexta / Venclyxto)
An oral BCL-2 inhibitor used in chronic lymphocytic leukaemia and in newly diagnosed acute myeloid leukaemia for adults unfit for intensive chemotherapy.
What is Venetoclax?
What it targets
The BCL-2 survival protein. Blocking BCL-2 restores apoptosis, so BCL-2-dependent leukaemia and lymphoma cells die instead of surviving abnormally.
Who it may help
Adults with CLL/SLL in frontline or relapsed settings, and older or unfit adults with newly diagnosed AML, usually as part of a combination plan chosen by a haematologist.
Why testing matters
Diagnosis must be confirmed and tumour lysis risk assessed before starting. Blood counts, kidney function, and drug interactions are checked, because rapid cell death can disturb blood chemistry.
Which cancers can Venetoclax treat?
Venetoclax is approved or used in the following blood cancers, usually as part of a combination regimen and always with a dose ramp-up.
| Chronic lymphocytic leukaemia / SLL (previously untreated) | Used in frontline combinations such as venetoclax with obinutuzumab (CLL14) and, as of 2026, the all-oral fixed-duration venetoclax with acalabrutinib regimen (AMPLIFY). |
| Chronic lymphocytic leukaemia / SLL (relapsed or refractory) | Used alone or with rituximab after earlier treatment, including in patients with del(17p) or TP53 mutation, supported by the MURANO trial. |
| Acute myeloid leukaemia (newly diagnosed, unfit for intensive chemo) | Combined with azacitidine, decitabine, or low-dose cytarabine in adults 75 or older, or with conditions that prevent intensive induction chemotherapy, supported by VIALE-A and VIALE-C. |
| Other blood cancers | Studied in clinical trials in myelodysplastic syndromes, multiple myeloma combinations, and lymphomas. Routine use depends on country approval, evidence, and specialist judgement. |
Are you eligible for Venetoclax?
Eligibility depends on a confirmed diagnosis, the treatment setting, tumour lysis risk, organ function, and drug interactions.
- Confirmed CLL/SLL, or newly diagnosed AML in an older or intensive-chemotherapy-ineligible adult
- A treatment setting where a venetoclax-based regimen is appropriate (frontline or relapsed)
- Tumour lysis syndrome risk assessed, with a plan for hydration and monitoring during ramp-up
- Adequate kidney function, or a plan to manage reduced kidney function safely
- Blood counts and infection risk acceptable for the planned combination
- A full medication review for CYP3A and P-glycoprotein interactions before starting
- Ability to follow the gradual dose ramp-up, frequent blood tests, and supportive measures
- No severe allergy to venetoclax or its tablet components
How does Venetoclax work?
- Understanding the BCL-2 survival signal
- Blocking BCL-2
- Rapid cell death and the need for ramp-up
- Working alongside other drugs
Venetoclax was the first BCL-2 inhibitor approved for cancer and is now part of several frontline and relapsed regimens in CLL and AML.
Tests required before starting Venetoclax
These tests confirm the diagnosis, establish baselines, and check for risks specific to venetoclax, especially tumour lysis syndrome.
| Diagnosis confirmation (flow cytometry, bone marrow) | Flow cytometry and CLL work-up, or bone marrow testing in AML, confirm the diagnosis and disease characteristics. |
| Complete blood count (CBC) with differential | Baseline red cell, white cell, and platelet counts, monitored closely throughout treatment. |
| Kidney and liver function tests | Assess organ function and dosing safety; kidney function strongly affects tumour lysis risk and monitoring. |
| Tumour lysis labs (uric acid, potassium, phosphate, calcium) | Checked at baseline and frequently during ramp-up because rapid cell death can disturb these values. |
| Genetic and molecular testing (FISH, TP53/del(17p), cytogenetics, NGS) | Used for prognosis and treatment planning in CLL and AML where available. |
| Tumour burden and lymph node assessment | Imaging or examination in CLL estimates tumour burden, which sets the tumour lysis risk category and monitoring intensity. |
| Medication review for drug interactions | Identifies CYP3A and P-glycoprotein inhibitors that may need adjustment before and during the ramp-up phase. |
How is Venetoclax given?
Venetoclax is taken as oral tablets, started at a low dose and increased gradually, with hydration, supportive medicines, and frequent blood monitoring.
| Route and how to take | Taken by mouth once daily with food and water. Tablets are swallowed whole and not chewed, crushed, or broken unless the team gives specific instructions. |
| The five-week ramp-up | In CLL the dose is increased weekly over five weeks, typically 20 mg, 50 mg, 100 mg, 200 mg, then 400 mg, to reduce tumour lysis risk. AML ramp-up is faster and given in hospital. |
| Hydration and supportive medicines | Fluids and uric-acid-lowering medicines such as allopurinol are given around dose increases to protect the kidneys and prevent tumour lysis syndrome. |
| Combination partners | Usually given with obinutuzumab, rituximab, or acalabrutinib in CLL, or with azacitidine, decitabine, or low-dose cytarabine in AML. |
| Monitoring schedule | Blood tests are frequent during ramp-up, sometimes with hospital monitoring for higher-risk patients, then spaced out once the target dose is reached and tolerated. |
| Duration | Fixed-duration in several CLL regimens, often around one to two years, or continued in cycles in AML until progression or unacceptable side effects. |
Clinical evidence and benefits
Venetoclax-based regimens have improved responses and progression-free survival across several large trials in CLL and AML.
| Fixed-duration frontline CLL | The CLL14 trial showed venetoclax with obinutuzumab, given for a fixed time, significantly improved progression-free survival versus an older standard in previously untreated CLL. |
| All-oral frontline CLL option | As of 2026, the AMPLIFY trial supported venetoclax with acalabrutinib as the first all-oral, fixed-duration regimen for previously untreated CLL, improving progression-free survival versus chemoimmunotherapy. |
| Relapsed or refractory CLL | The MURANO trial showed venetoclax with rituximab significantly improved progression-free survival versus chemoimmunotherapy after earlier treatment, including in higher-risk disease. |
| AML in unfit patients | The VIALE-A and VIALE-C trials showed venetoclax combined with azacitidine or low-dose cytarabine improved outcomes in newly diagnosed AML patients unable to receive intensive chemotherapy. |
| An oral, non-chemotherapy mechanism | Venetoclax offers a targeted oral option that can be combined flexibly and, in many CLL settings, allows a planned end point with time off treatment. |
Individual responses vary with disease biology, genetic risk, prior treatment, and organ function. These reflect published clinical trial data and not a promise of outcome.
Side effects of Venetoclax
Venetoclax is generally manageable, but side effects are common and depend on the drugs it is combined with. Most are monitored and treatable, but some are serious.
| Tumour lysis syndrome | The most important early risk; rapid cell breakdown can disturb blood chemistry and harm the kidneys. Prevented by ramp-up, hydration, and close monitoring. |
| Low white blood cells (neutropenia) | Very common, sometimes severe; counts are monitored and doses interrupted or supported with growth factors if needed. |
| Low platelets and anaemia | Common, and managed with monitoring, dose changes, and transfusions when required. |
| Infections | Increased risk, including chest infections; fever or new symptoms should be reported promptly. |
| Nausea, vomiting, or diarrhoea | Common and usually manageable with diet and supportive medicines. |
| Constipation | Can occur, particularly with combination regimens, and is managed with supportive care. |
| Fatigue | Common, often mild to moderate, and may improve over time. |
| Muscle or joint pain | Common with blood cancer combinations and managed with supportive care. |
Contact your doctor or go to hospital immediately if you develop:
- Reduced urination, dark urine, severe weakness, or confusion (possible tumour lysis syndrome)
- High fever, chills, or other signs of serious infection
- Unusual bruising, bleeding, or signs of very low blood counts
- Persistent vomiting, severe diarrhoea, or an irregular heartbeat
- Breathlessness, chest pain, or severe dizziness or fainting
Safety precautions and key warnings
Tell your oncologist about your full medical history, all medicines and supplements, and any kidney or infection problems before starting venetoclax.
- Tumour lysis syndrome is the key risk — the ramp-up, hydration, and blood tests must be followed exactly as instructed
- Tell your team about any kidney disease, gout, or high uric acid, as these raise tumour lysis risk
- Strong or moderate CYP3A inhibitors and P-glycoprotein inhibitors can raise venetoclax levels and may need to be avoided or adjusted during ramp-up
- Avoid grapefruit, Seville oranges, and starfruit while taking venetoclax
- Report fever or new symptoms promptly, as infection risk is increased; vaccinations may be advised before starting
- Tell your team about repeated infections, lung disease, heart disease, or bleeding problems
- Pregnancy should be avoided; discuss contraception and breastfeeding with your oncologist
Venetoclax combination treatments
Venetoclax is almost always used in combination, because pairing it with other drug classes attacks the cancer through different pathways.
| Venetoclax + obinutuzumab | Fixed-duration frontline therapy for previously untreated CLL (CLL14), often around one year of treatment. |
| Venetoclax + acalabrutinib (± obinutuzumab) | All-oral, fixed-duration frontline CLL regimen approved in 2026 based on the AMPLIFY trial. |
| Venetoclax + rituximab | Fixed-duration regimen for relapsed or refractory CLL after earlier treatment (MURANO). |
| Venetoclax + azacitidine or decitabine | Frontline AML therapy for older or unfit adults, given in cycles (VIALE-A). |
| Venetoclax + low-dose cytarabine | An AML option for selected unfit adults where a hypomethylating agent is not used (VIALE-C). |
| Switching or next-line therapy | If venetoclax stops working, options include BTK inhibitors, other targeted drugs, transplant, CAR T-cell therapy, or a clinical trial. |
If Venetoclax stops working
Blood cancers can become resistant over time. Understanding why helps guide the next step.
| Changes in BCL-2 and related proteins | Cancer cells can develop changes that reduce venetoclax binding or shift their survival to other proteins, lowering the drug's effect. |
| Prior drug exposure | Outcomes depend on which classes you have already received, including BTK inhibitors, chemoimmunotherapy, and hypomethylating agents, all of which are reviewed. |
| Re-testing at progression | Blood and bone marrow tests are repeated, flow cytometry may be redone, and cytogenetic or molecular risk is reassessed. |
| Next-line options | These can include a BTK inhibitor, other targeted therapy, antibody treatment, chemotherapy, stem cell transplant, CAR T-cell therapy, or a clinical trial. |
| Supportive care | Management of low blood counts, infection risk, bleeding, and other complications continues alongside any change in therapy. |
Cost of Venetoclax by country
Venetoclax is a branded oral targeted therapy without a widely available generic, so cost depends on the dose, treatment duration, combination drugs, monitoring, and insurance. Always ask for a full written estimate.
| India | Available at major cancer centres; cost varies by dose, treatment duration, and combination drugs such as obinutuzumab or azacitidine. Hospital pharmacies and patient-support routes may help — ask for a full treatment-plan estimate. |
| China | Used in leading cancer hospitals; pricing and access depend on hospital procurement, insurance category, and the approved indication. CancerFax can help check practical access. |
| USA | High list price without insurance; most patients are covered through insurance, and manufacturer patient-assistance programmes may apply for eligible patients. |
| UK / Europe | Available through national health systems for approved indications, usually with minimal out-of-pocket cost for covered patients; self-pay costs are substantial. |
Availability of Venetoclax globally
Venetoclax is available in many major cancer markets, though the exact approved indications and combinations vary by country and hospital.
India
Available at major cancer hospitals for CLL and AML. Approved indications and access depend on registration and hospital procurement. CancerFax can help check access and second-opinion pathways.
China
Used in leading cancer centres for blood cancers. Access depends on hospital procurement, the approved indication, and insurance category. CancerFax supports patients exploring treatment in Chinese oncology centres.
USA
Approved for CLL/SLL, including frontline and relapsed disease and an all-oral fixed-duration regimen, and for newly diagnosed AML in older or unfit adults.
Europe
Authorised as Venclyxto for CLL and for AML in specific settings, and covered by national health systems for approved indications.
Venetoclax in current clinical trials
Research continues into using venetoclax in new combinations, in more disease settings, and guided by minimal residual disease testing.
| MRD-guided fixed-duration regimens | Trials testing how minimal residual disease results can personalise how long venetoclax combinations are given in CLL. |
| New AML and MDS combinations | Studies combining venetoclax with newer targeted agents and exploring use in myelodysplastic syndromes and high-risk disease. |
| Beyond CLL and AML | Research into venetoclax in multiple myeloma subsets, lymphomas, and mutation-selected strategies, with access varying by country and hospital. |
Your treatment journey with Venetoclax
Diagnosis and baseline testing
Tumour lysis risk assessment and planning
Starting the ramp-up
Reaching the target dose
Monitoring and response assessment
Completion or change of plan
Questions to ask your oncologist about Venetoclax
- Is Venetoclax suitable for my type of leukaemia and treatment stage?
- What is my tumour lysis syndrome risk, and how will it be managed?
- Which drugs will be combined with Venetoclax?
- Do I need to stop or change any of my current medicines?
- What does the dose ramp-up involve and how long does it take?
- What side effects should I report urgently?
- How long will I need to take Venetoclax?
- What are my options if Venetoclax stops working?
How CancerFax supports Venetoclax patients
CancerFax helps leukaemia patients and families understand their reports, weigh their options, and access the right treatment.
| Report review | Upload your flow cytometry, bone marrow, genetic, and blood reports — our team reviews them and explains what they mean for venetoclax and other treatment options. |
| Specialist connection | We connect patients with haematologists and leukaemia specialists experienced in venetoclax-based regimens in India, China, and other centres. |
| Second opinion | If you are unsure about your regimen, or the leukaemia has relapsed, CancerFax arranges an expert second opinion. |
| Access and cost navigation | We help check practical availability, the approved indication, and hospital options, and provide treatment-plan cost estimates where possible. |
| Advanced therapy guidance | For patients who may need a BTK inhibitor, stem cell transplant, or CAR T-cell therapy, CancerFax helps explore appropriate options and clinical trials. |
Frequently asked questions about Venetoclax
Common questions from patients and caregivers
Venetoclax is an oral targeted therapy, not traditional chemotherapy. It blocks a survival protein called BCL-2 that some leukaemia and lymphoma cells rely on to avoid natural cell death. By switching that survival signal off, it helps the cancer cells self-destruct. Because it works on a specific target rather than broadly attacking all dividing cells, its side-effect pattern is different, though it still needs careful blood monitoring and a slow dose build-up.
Venetoclax can kill cancer cells very quickly. If too many cells break down at once, it can cause tumour lysis syndrome, which disturbs the body's blood chemistry and can harm the kidneys. To reduce this risk, every venetoclax regimen begins with a gradual five-week ramp-up, usually starting at 20 mg daily and increasing step by step under close supervision with blood tests and hydration.
Tumour lysis syndrome happens when many cancer cells die rapidly and release their contents into the blood, raising potassium, phosphate, and uric acid and stressing the kidneys. It is the most important early risk with venetoclax. Your team prevents it with the slow dose ramp-up, plenty of fluids, uric-acid-lowering medicines, and frequent blood tests in the first weeks, sometimes with monitoring in hospital for higher-risk patients.
Venetoclax is broken down by the CYP3A pathway, so strong CYP3A inhibitors and P-glycoprotein inhibitors can raise its level and increase the risk of tumour lysis syndrome, especially during the ramp-up. Grapefruit, Seville oranges, and starfruit should be avoided. Always give your oncologist a full list of your medicines, including antifungals, antibiotics, heart medicines, and herbal products, before and during treatment.
It depends on your disease and regimen. In CLL, several venetoclax combinations are given for a fixed duration, for example around one to two years, after which treatment stops and you are monitored. In AML, venetoclax with azacitidine or another partner usually continues in cycles for as long as it keeps working and is tolerated. Your oncologist will tell you which plan applies to you.
If the leukaemia grows or blood counts worsen, your doctor will recheck blood and bone marrow tests and may repeat flow cytometry, cytogenetics, or molecular testing. Next options depend on what you have already received and can include a BTK inhibitor, other targeted drugs, chemotherapy, antibody therapy, stem cell transplant, cellular therapy such as CAR T-cell therapy, or a clinical trial. A specialist second opinion can help identify the best next step.
Venetoclax is approved and used in many countries, including the USA, Europe, India, and China, though the exact approved indications, brand, and access route can differ by country and hospital. Not every regimen is available everywhere. CancerFax can help you check practical availability, hospital options, and second-opinion pathways across India, China, and other centres.